Skip to main content

Table 6 Comparison of the areas under ROC for NLR and other biomarkers to predict future exacerbations and low % FEV1 (% FEV1 < 50%)

From: Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

Exacerbation

AUC (95% CI)

 NLR

63.4 (55.0–71.7)

 Neutrophil count

55.2 (46.3–64.2)

 Lymphocyte count

59.2 (50.8–67.6)

 Eosinophil count

51.2 (41.9–60.6)

 CRP

54.3 (45.2–63.4)

 SAA

59.4 (50.5–68.3)

% FEV1 < 50%

AUC (95% CI)

 NLR

64.2 (56.9–71.6)

 Neutrophil count

55.3 (47.3–63.2)

 lymphocyte count

59.8 (52.3–67.3)

 Eosinophil count

51.5 (43.4–59.6)

 CRP

55.5 (47.7–63.5)

 SAA

57.7 (49.8–65.6)

  1. NLR Neutrophil-to-Lymphocyte ratio, CRP C-reactive protein, SAA serum amyloid A